BioPharma Credit PLC, a specialist lender to small and mid-sized life sciences companies, reported first-half 2026 results on September 25, highlighting a portfolio characterized by steady returns and selective exposure. The company delivered net income per share of $0.045 for the period, reflecting a 7.7% gain from its December 2025 close of $0.91 to a recent trading price of $0.98. Year-to-date, the share has advanced 13.89%, with a 52-week range spanning $0.876 to $1.00. With a market capitalization of $1.1 billion and a trailing P/E ratio of 8.59, BioPharma Credit’s valuation remains anchored by a 10.23% dividend yield and a stock beta of 0.18, indicating low market volatility relative to peers.
The portfolio, valued at approximately $3.0 billion as of September 2026, includes a parallel private fund launched in 2019 that has grown to about $1.9 billion, with expectations to surpass $2 billion by year-end. Liquidity available for sale stands at roughly $45 million. The largest single position—$550 million, or 19% of assets—belongs to Insmed, a biopharmaceutical company expected to repay or refinance its loan by October 2027. Insmed’s projected sales exceed $1.5 billion with gross margins in the high 90s, and cash generation is anticipated to exceed $1 billion annually.
Convertible debt exposure remains minimal at 2.2% of the portfolio, while other notable investments include a $150 million Swiss franc loan to Idorsia for its sleep disorder drug QUVIVIQ, hedged at an effective rate of approximately 10.8% in dollars. Idorsia’s sales are expected to exceed CHF 200 million this year, following prior guidance of CHF 134 million. A recent addition is a loan to Kestra Medical Technologies, a wearable heart-attack monitoring device maker, structured at SOFR plus 550 basis points.
Management emphasized a disciplined approach to collateral valuation, citing the underlying value of life sciences assets as significantly higher than the debt obligations. The company’s 10-year dividend track record and consistent returns—described as “boring but attractive”—reflect a strategy focused on selective, high-quality exposures. BioPharma Credit aims to capture $1.5 billion to $2 billion of the estimated $4 billion to $5 billion annual lending market for life sciences firms.
The portfolio includes other notable positions, such as Biogen/Reata’s one-time settlement payment of over $8 million and a full recovery of initial investment in Lumira Colombia, marking the first default encountered in Pharmakon’s 17-year history. Mineralys, a U.S.-based pre-approval investment, is set for FDA action on December 22, 2026.
With a team of 10 professionals, including key partners, BioPharma Credit operates a rigorous due diligence process, tracking over 300 healthcare companies annually through 14 key conferences. The junior investment team requires 2 to 3 years of healthcare banking experience, reflecting a focus on deep expertise in the sector.
